Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease
- PMID: 23879671
- DOI: 10.1111/ijd.12144
Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease
Abstract
Objective: The aim of this study was to investigate the effects of azithromycin on mucocutaneous manifestations and ex vivo intracellular cytokine responses in patients with Behçet's disease (BD).
Methods: Ten BD patients with active manifestations and nine healthy controls (HCs) were included in the study. Patients were treated with azithromycin (1500 mg/week) for four weeks. Clinical and immunological responses were evaluated in the pre- and post-azithromycin treatment periods. Peripheral blood mononuclear cells (PBMCs) of patients and controls were stimulated by Streptococcus sanguinis, lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat shock protein-60 (HSP-60) for three hours. Ex vivo intracellular interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels were measured.
Results: Follicular lesions and genital ulcers completely healed, and the number of oral ulcers decreased after treatment (P = 0.000). The stimulated intracellular IFN-γ response to S. sanguinis was higher in BD patients (5.75%) than in HCs (3.9%) before treatment (P = 0.05). Likewise, the pretreatment IFN-γ response was significantly higher than the post-treatment response (1.95%). In BD patients, pretreatment stimulated intracellular IFN-γ responses to LTA (5.8%) were also higher than post-treatment responses (3.15%), but the difference did not reach statistical significance (P = 0.07).
Conclusions: Azithromycin treatment decreased the mucocutaneous manifestations in BD patients and suppressed the intracellular IFN-γ responses of PBMCs to S. sanguinis ex vivo, which suggests this treatment has an immunomodulatory effect.
© 2013 The International Society of Dermatology.
Similar articles
-
Clinical and immunological effects of azithromycin in Behçet's disease.J Oral Pathol Med. 2005 Jan;34(1):13-6. doi: 10.1111/j.1600-0714.2004.00265.x. J Oral Pathol Med. 2005. PMID: 15610401
-
TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease.Br J Dermatol. 2006 Aug;155(2):350-6. doi: 10.1111/j.1365-2133.2006.07348.x. Br J Dermatol. 2006. PMID: 16882174
-
Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.J Rheumatol. 2005 Jan;32(1):98-105. J Rheumatol. 2005. PMID: 15630733 Clinical Trial.
-
Behçet's disease: treatment of mucocutaneous lesions.Clin Exp Rheumatol. 2005 Jul-Aug;23(4):532-9. Clin Exp Rheumatol. 2005. PMID: 16095126 Review.
-
Mucocutaneous lesions of Behcet's disease.Yonsei Med J. 2007 Aug 31;48(4):573-85. doi: 10.3349/ymj.2007.48.4.573. Yonsei Med J. 2007. PMID: 17722228 Free PMC article. Review.
Cited by
-
Innate immune responses in Behçet disease and relapsing polychondritis.Front Med (Lausanne). 2023 Jun 26;10:1055753. doi: 10.3389/fmed.2023.1055753. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37435539 Free PMC article. Review.
-
Treatment Options in Pediatric Behçet's Disease.Paediatr Drugs. 2023 Mar;25(2):165-191. doi: 10.1007/s40272-022-00548-5. Epub 2023 Jan 10. Paediatr Drugs. 2023. PMID: 36626047 Free PMC article. Review.
-
Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.Front Immunol. 2021 Dec 22;12:724900. doi: 10.3389/fimmu.2021.724900. eCollection 2021. Front Immunol. 2021. PMID: 35003055 Free PMC article.
-
Oral Health and Its Aetiological Role in Behçet's Disease.Front Med (Lausanne). 2021 May 20;8:613419. doi: 10.3389/fmed.2021.613419. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34095159 Free PMC article. Review.
-
Advances in the Treatment of Behcet's Disease.Curr Rheumatol Rep. 2021 May 20;23(6):47. doi: 10.1007/s11926-021-01011-z. Curr Rheumatol Rep. 2021. PMID: 34014377 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
